

May 31, 2016

(Electronically Filed)
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P O Box 1450
Alexandria, VA 22313-1450

Inter Partes Review IPR2016-01096 (U.S. Patent No. 6,667,061)
Exhibit Cover Letter Per 37 C.F.R. § 42.6(e)(4)(ii)

Dear Patent Trial and Appeal Board:

This transmittal letter identifies Exhibits 1001-1003, 1005-1023, being filed concurrently with the present Petition for *Inter Partes* Review. Pursuant to 37 C.F.R. § 42.6(e)(4)(ii), the Certificate of Service attached to the end of the Petition for *Inter Partes* Review filed herewith, incorporates Exhibits 1001-1003, 1005-1023, as listed below:

EXHIBIT LIST

Exhibit #	Reference
1001	U.S. Patent No. 6,667,061 (“the ’061 Patent”)
1002	Declaration of Dr. Patrick P. DeLuca
1003	<i>Curriculum Vitae</i> of Dr. Patrick P. DeLuca
1004	Intentionally Left Blank
1005	International Publication No. WO 95/13799 (“Ramstack”)
1006	U.S. Pharmacopeia Entry re: CMC, viscosity pp.274-75, 1840 (1994)
1007	EP Pharmacopoeia Entry re: CMC, pp.547-48(3d ed. 1997)
1008	Handbook of Pharmaceutical Excipients pp.78-81, 135-38, 294-95, 329-330, 375-78, 420-21, 439-42, 477-80, 481-82 (2nd ed. 1994)
1009	U.S. Patent No. 5,654,010 (“Johnson”)
1010	U.S. Patent No. 5,656,299 (“Kino”)
1011	International Publication No. WO199714408 (“Gustafsson”)
1012	Intentionally Left Blank
1013	Intentionally Left Blank
1014	Herbert A. Lieberman <i>et al.</i> (eds.), <i>Pharmaceutical Dosage Forms: Disperse Systems</i> , Vol.2, pp.26-35, 40, 43-46, 261, 285-318 (2nd ed. rev. expanded 1996)
1015	U.S. Patent No. 6,495,164 (“the ’164 Patent”)
1016	Serial No. 10/259,949, Office Action, Apr. 9, 2003

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
May 31, 2016
Page 2

Exhibit #	Reference
1017	Serial No. 10/259,949, Applicants' Resp., May 14, 2003
1018	Serial No. 09/577,875, Declaration of Mark A. Tracy, May 17, 2002
1019	Serial No. 10/259,949, Notice of Allowability, July 24, 2003
1020	Kenneth E. Avis <i>et al.</i> (eds.), 1 (Chs.2, 4, 5) <i>Pharmaceutical Dosage Forms: Parenteral Medications</i> 17-25, 115-16, 140-43, 150-51, 173-75, 190-212 (2nd ed. rev. expanded Marcel Dekker, Inc. 1992)
1021	Leon Lachman, PhD <i>et al.</i> , <i>The Theory and Practice of Industrial Pharmacy</i> 642-44, 783-84 (Lea & Febiger 3rd ed. 1986)
1022	Herbert A. Lieberman <i>et al.</i> , <i>Pharmaceutical Dosage Forms: Disperse Systems</i> , Vol.1, pp.287-313 (2nd ed. rev. expanded 1996)
1023	Orange Book entries for RISPERDAL [®]

Respectfully submitted,

LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP



William L. Mentlik
Reg. No. 27,108

WLM/dmf